Overview

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is assessing how 64Cu-ATSM (64Cu-copper(II) diacetylbis(N4-methylthiosemicarbazone)) PET/CT scan could predict neo adjuvant treatment response in rectum cancer locally advanced
Phase:
Phase 2
Details
Lead Sponsor:
Institut Cancerologie de l'Ouest
Collaborator:
Fondation ARC